News

Parent company, ValiRx Plc, a life science company focusing on early-stage cancer therapeutics and women’s health, entered into a nine-month evaluation agreement with The Royal Institute for the advancement of Learning / McGill University (“McGill”), a Canadian based University and The Institute for Research in Immunology, and Cancer – Commercialization of Research (“IRICoR”), a Canadian…

Ascites represents a particularly valuable source of tumour material as it enables minimally invasive and repeatable sampling of metastatic disease, yields substantially higher numbers of viable tumour cells than solid tumour biopsy and is associated with improved PDC establishment success rates. Unlike solid tumour processing, ascites derived cultures require minimal tissue dissociation, reducing processing associated…

Inaphaea Biolabs Ltd, the wholly owned subsidiary of ValiRx plc, focused on advanced in-vitro and translational biology services, has announced a new nine-month Evaluation and Material Transfer Agreement with The Royal Institution for the Advancement of Learning/McGill University and the Institute for Research in Immunology and Cancer – Commercialisation of Research (IRICoR). Under the agreement,…

Dr Cathy Tralau-Stewart is an experienced therapeutics development scientist and pharmacologist. Working within some of the world’s leading pharma and academic research establishments, she has developed a broad knowledge of drug discovery and the translation of early research innovation into developable drug discovery programs. Cathy has been with ValiRx Plc since September 2022 when she…

Inaphaea continues to drive innovation in drug development through its cutting-edge work with Patient-Derived Cells (PDCs), advanced in-silico modelling, and strategic collaborations. By partnering with leading academic institutions and industry innovators, Inaphaea is enhancing predictive disease models, accelerating drug discovery, and advancing targeted therapies for cancer. Collaborative updates Inaphaea is delighted to confirm the completion…

Inaphaea BioLabs, a pioneering translational research organisation based in Nottingham, has announced a series of strategic collaborations and research advances that significantly strengthen its position at the forefront of personalised cancer therapy development. As part of its ongoing expansion of capability partnerships, Inaphaea has signed a Collaboration Agreement with Swiss techbio innovator TwinEdge Bioscience. TwinEdge,…

Inaphaea BioLabs, the wholly owned translational Contract Research Organisation of ValiRx Plc, has announced a series of major initiatives over the past three months that significantly advance its role in translational cancer research, drug discovery, and personalised medicine.  Under the leadership of Mark Eccleston, the recently appointed CEO of parent company ValiRx, both ValiRx and…

Inaphaea BioLabs, the translational Contract Research Organisation (tCRO) wholly owned by ValiRx Plc, will play a pivotal role in the development of a newly established subsidiary, Blue Ribbon Bio Limited, dedicated to advancing prostate cancer therapeutics. Blue Ribbon will house all prostate cancer–associated assets from ValiRx, beginning with Val201, an investigational peptide therapeutic originally licensed…

Inaphaea BioLabs Limited, the wholly owned subsidiary of ValiRx Plc, specialising in advanced patient-derived cell (PDC) models, has been awarded a Knowledge Transfer Voucher (KTV) by The Open University to support cutting-edge imaging and machine learning research in 3D tumour models. The project, running from 1 August 2025 to 30 September 2026, will leverage the…

Earlier this month, ValiRx Plc, a life science company focused on early-stage cancer therapeutics and women’s health, announced a new 12-month agreement with Stingray Bio Limited (“Stingray”), placing its wholly owned subsidiary, Inaphaea BioLabs, at the centre of a hybrid evaluation and development programme for promising oncology drug candidates. The agreement builds on Inaphaea’s extensive…